Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience Jackson C; Sirohi B; Cunningham D; Horwich A; Thomas K; Wotherspoon AAnn Oncol 2010[Oct]; 21 (10): 2061-2068BACKGROUND: Lymphocyte-predominant Hodgkin disease (LPHD) is a rare subtype of Hodgkin lymphoma, for which there is limited evidence regarding the presentation, natural history and treatment outcomes. PATIENTS AND METHODS: We conducted a single-institution retrospective review all of patients diagnosed with LPHD over a 30-year period. RESULTS: Eighty-eight patients were included. Median follow-up was 13 years. Local radiotherapy or chemoradiotherapy resulted in durable disease control in patients with stage I or II disease. Advanced stage at presentation, presence of B symptoms, low albumin, and either partial response or stable disease to first treatment were associated with worse treatment outcomes. Relapse rate for the entire cohort was 44%, with an 8% rate of transformation to large-cell lymphoma. Rituximab in combination with chemotherapy resulted in durable remission in a heavily pretreated subgroup. Outcomes with autologous transplant are discussed. CONCLUSION: Our series has the longest follow-up of any report, includes the only series of patients treated with autologous transplant, and has the largest group of patients treated with rituximab and chemotherapy in this indication.|*Stem Cell Transplantation[MESH]|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Child[MESH]|Combined Modality Therapy[MESH]|Female[MESH]|Hodgkin Disease/pathology/*therapy[MESH]|Humans[MESH]|Lymphocytes/drug effects/*pathology/radiation effects[MESH]|Lymphoma, Large B-Cell, Diffuse/pathology/*therapy[MESH]|Male[MESH]|Middle Aged[MESH]|Neoplasm Staging[MESH]|Radiotherapy Dosage[MESH]|Remission Induction[MESH]|Retrospective Studies[MESH]|Survival Rate[MESH]|Treatment Outcome[MESH]|Young Adult[MESH] |
